05/04/2013

Fidia Farmaceutici s.p.a. and BMG Pharma s.r.l. have entered into a partnership to promote and sell IALECT® topical gel in Italy

New addition in the company's dermatological portfolio

Abano Terme (Italy) and Milan (Italy) April 3, 2013 - Fidia Farmaceutici S.p.A. (Abano Terme, Italy) and BMG Pharma S.r.l. (Milan, Italy) are pleased to announce that they have signed an exclusive distribution agreement granting Fidia the rights to promote, market and sell BMG Pharma's topical gel in Italy, under the brand name IALECT® GEL.

Under the terms of this agreement, BMG Pharma will receive an undisclosed down payment from Fidia, which shall buy all its requirements of IALECT® GEL from BMG Pharma.

IALECT® GEL is a unique combination gel formulation which can be used to treat acne lesions, folliculitis, paronychia, and impetigo. The key ingredients in this novel formulation - hyaluronic acid and hydrogen peroxide - associate antiseptic and healing properties and work synergistically to provide a highly protective activity and effective filmogenic barrier to the skin.

"BMG Pharma's working team has been strongly committed in the invention and creation of major medical devices for the treatment of acne lesions, folliculitis, paronychia, and impetigo." - said Marco Mastrodonato, President and CEO of BMG Pharma S.r.l. - "We are therefore pleased to partner with Fidia Farmaceutici, a leading company in dermatology and we believe this agreement will be beneficial to both parties".

"We are pleased to have entered into a partnership with BMG Pharma S.r.l. to promote and sell IALECT® GEL in Italy" - said Giorgio Foresti, CEO of Fidia Farmaceutici SpA - "since this product is aligned with our strategy to complement our existing dermatological portfolio for the Italian market and offer a wide range of treatments with products based on hyaluronic acid."

About BMG Pharma S.r.l
BMG Pharma S.r.l. is a Specialty Pharmaceutical Company leveraging its proprietary technology to develop products that address unmet needs of patients. The Company is currently focused on cancer supportive care, dermatology gynecology, ENT and oral health. BMG Pharma S.r.l. is dedicated to helping patients, pharmacists and physicians by providing valuable and innovative products to the market.
For press releases and other Company information, visit www.bmgpharma.com
Source: Company news

Health
Products
Website

Find out more about Fidia’s product portfolio:

Go to the website

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint healthcare
- ophthalmology
- wound care
- dermatology
- neurology
- dermo-aesthetics